(DHA) Inhibit Angiogenesis, Tumor Growth, and Metastasis
Total Page:16
File Type:pdf, Size:1020Kb
Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis Guodong Zhanga,b, Dipak Panigrahyc,d, Lisa M. Mahakiane, Jun Yanga,b, Jun-Yan Liua,b, Kin Sing Stephen Leea,b, Hiromi I. Wetterstenf, Arzu Ulua,b, Xiaowen Hue, Sarah Tame, Sung Hee Hwanga,b, Elizabeth S. Inghame, Mark W. Kieranc,g, Robert H. Weissb,f,h, Katherine W. Ferrarae, and Bruce D. Hammocka,b,1 aDepartment of Entomology, and bComprehensive Cancer Center, University of California, Davis, CA 95616; cVascular Biology Program, Children’s Hospital Boston, and dDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115; eDepartment of Biomedical Engineering, and fDivision of Nephrology, Department of Internal Medicine, University of California, Davis, CA 95616; gDivision of Pediatric Oncology, Dana- Farber Cancer Institute, Harvard Medical School, Boston, MA 02115; and hUS Department of Veteran’s Affairs Medical Center, Sacramento, CA 95655 Contributed by Bruce D. Hammock, March 8, 2013 (sent for review December 24, 2012) Epidemiological and preclinical evidence supports that omega-3 proangiogenic (25–27) and have been shown to accelerate tumor dietary fatty acids (fish oil) reduce the risks of macular degenera- growth and metastasis by stimulation of tumor angiogenesis (28), tion and cancers, but the mechanisms by which these omega-3 whereas the roles of EDPs in angiogenesis and tumorigenesis lipids inhibit angiogenesis and tumorigenesis are poorly under- have not been studied to date. To this end, we investigated the stood. Here we show that epoxydocosapentaenoic acids (EDPs), actions of EDPs on angiogenesis, tumor growth, and metastasis. which are lipid mediators produced by cytochrome P450 epoxyge- nases from omega-3 fatty acid docosahexaenoic acid, inhibit VEGF- Results and fibroblast growth factor 2-induced angiogenesis in vivo, and EDP Inhibits Angiogenesis in Vivo. To test the actions of EDPs on suppress endothelial cell migration and protease production in angiogenesis, we chemically synthesized all stable EDP regioisom- vitro via a VEGF receptor 2-dependent mechanism. When EDPs ers including 7,8-, 10,11-, 13,14-, 16,17- and 19,20-EDP (4,5-EDP is (0.05 mg·kg−1·d−1) are coadministered with a low-dose soluble chemically unstable) (22) and evaluated their effects on angiogen- epoxide hydrolase inhibitor, EDPs are stabilized in circulation, caus- esis using a Matrigel plug assay in mice (29). Vascular endothelial ing ∼70%inhibitionofprimarytumorgrowthandmetastasis.Con- growth factor (VEGF) is the most important regulator in path- trary to the effects of EDPs, the corresponding metabolites derived ological angiogenesis (30). Implantation of Matrigel plugs con- MEDICAL SCIENCES from omega-6 arachidonic acid, epoxyeicosatrienoic acids, increase taining 100 ng VEGF in mice triggered a robust angiogenic angiogenesis and tumor progression. These results designate response after 4 d of treatment. Addition of 19,20-EDP in the epoxyeicosatrienoic acids and EDPs as unique endogenous media- gel significantly inhibited VEGF-induced angiogenesis in a dose- tors of an angiogenic switch to regulate tumorigenesis and impli- dependent manner, with an EC50 value ∼0.3 μg per gel, illustrating cate a unique mechanistic linkage between omega-3 and omega-6 a potent antiangiogenic effect of 19,20-EDP in vivo (Fig. 1A). We fatty acids and cancers. tested other EDP regioisomers and found all five regioisomers dramatically inhibited VEGF-induced angiogenesis (Fig. 1B). The pidemiological and preclinical evidence supports that a diet 19,20-EDP also significantly inhibited fibroblast growth factor Erich in omega-3 dietary fatty acids is correlated with reduced 2 (FGF-2)–induced angiogenesis (Fig. S1), demonstrating the risks of angiogenic diseases such as macular degeneration (1–4) potential broad-spectrum antiangiogenic effects of EDPs. – and cancers (5 8). However, the mechanisms by which omega-3 fi fatty acids inhibit angiogenesis and cancer are poorly under- EDP Inhibits Angiogenesis in Vitro. Given these in vivo ndings in a stood. A widely accepted theory to explain the health-promoting model system, we next studied whether EDPs have direct anti- effects of omega-3 fatty acids is that they suppress the metabo- angiogenic actions on human endothelial cells. Because 19,20- lism of omega-6 arachidonic acid (ARA) to form proangiogenic EDP is the most abundant EDP regioisomer detected in vivo (16, 19), we focused on this isomer. The 19,20-EDP dramatically in- or proinflammatory eicosanoids or serve as alternative substrates hibited endothelial tube formation after a 6-h treatment in human to generate omega-3 lipid mediators with beneficial actions (9). umbilical vein endothelial cells (HUVECs), ∼63% inhibition at Indeed, the metabolism of omega-3 fatty acids by cyclooxygenase 1 μMand∼91% inhibition at 3 μM, demonstrating its potent (COX) and lipoxygenase (LOX) enzymes generates 3-series pros- antiangiogenic effect in vitro (Fig. 1C). In comparison, DHA had taglandins (10, 11) and leukotrienes (12), as well as unique omega-3 no such effect (Fig. S2 A and B). Because angiogenesis involves autacoids such as resolvins and protectins (13), which have anti- fl multiple cellular steps including endothelial cell migration, pro- in ammatory or antiangiogenic effects. liferation, and production of proteases (31), we studied the step at Besides the intensively studied COX and LOX pathways, which 19,20-EDP inhibited angiogenesis. The 19,20-EDP inhibi- omega-3 and omega-6 fatty acids are also substrates of cyto- ted VEGF-induced HUVEC migration on extracellular matrix chrome P450 (CYP) epoxygenases, which convert them to epoxy (ECM) proteins fibronectin and vitronectin at a similar potency signaling lipids including epoxyeicosatrienoic acids (EETs) de- (∼50% reduction at 1 μM and ∼70% reduction at 3 μM, Fig. 1D rived from omega-6 ARA and epoxydocosapentaenoic acids (EDPs) from omega-3 docosahexaenoic acid (DHA) (14–16). DHA, which is the most abundant omega-3 fatty acid in most Author contributions: G.Z., D.P., M.W.K., K.W.F., and B.D.H. designed research; G.Z., D.P., tissues (17, 18), can efficiently compete with ARA for the me- L.M.M., J.Y., J.-Y.L., K.S.S.L., H.I.W., A.U., X.H., S.T., and E.S.I. performed research; K.S.S.L. tabolism by CYP epoxygenases, leading to replacement of EETs and S.H.H. contributed new reagents/analytic tools; G.Z., D.P., J.Y., J.-Y.L., H.I.W., R.H.W., with EDPs in vivo (16, 19, 20). EETs and EDPs have been in- K.W.F., and B.D.H. analyzed data; and G.Z., D.P., J.Y., J.-Y.L., M.W.K., R.H.W., K.W.F., and B.D.H. wrote the paper. vestigated as autocrine and paracrine mediators to regulate in- fl – Conflict of interest statement: University of California holds patents from the labora- ammation and vascular tone (21 24). In comparison, EDPs have tory of B.D.H. on sEHI for the treatment of inflammation, hypertension, pain and other been reported to have more potency on vasodilation and anti- indications. inflammation than EETs (22, 24). Cumulatively, these results 1To whom correspondence should be addressed. E-mail: [email protected]. imply that EDPs could mediate some of the health-promoting This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. effects of DHA. In terms of angiogenesis and cancer, EETs are 1073/pnas.1304321110/-/DCSupplemental. www.pnas.org/cgi/doi/10.1073/pnas.1304321110 PNAS Early Edition | 1of6 Downloaded by guest on October 1, 2021 HO HO HO HO HO A B O O O O O CD31 O 140 VEGF + 140 O 120 Vehicle 100 120 O 100 80 O ** 80 60 O 60 40 # CD31 Hemoglobin VEGF + 40 # # 20 # 10 μg Hemoglobin 20 # (mg protein per g gel) g per protein (mg # 0 19,20-EDP # Ctrl 0.3 3 10 protein per g gel)(mg 0 rl P P P P P t D D D D D 19,20-EDP (mg in gel) C E E E 8- 1-E 4- 7-E 0- 7, ,1 ,1 ,1 ,2 10 13 16 19 Tube formaon C 120 100 80 60 # 40 20 # 0 Branching Points (%) Endothelial cell migraon 120 D 100 80 # 60 # 40 20 0 Ctrl 19,20-EDP (1 μM) 19,20-EDP (3 μM) HUVEC Migration (%) Ctrl 1 3 19,20-EDP (mM) E120 F GVEGF-A P-VEGFR2 140 VEGF-C 100 # 120 80 β-acn 100 19,20- 11,12 DMSO # DMSO 60 80 40 60 ## - EDP EET ## 20 (no 40 MMP-2 Activity (%) MMP-2 Activity 0 VEGF) 20 Ctrl 1 3 0 VEGF (50 ng/mL) 19,20-EDP (mM) Ctrl 1 3 mRNA expression (% to Ctrl) mRNA 19,20-EDP (mM) Fig. 1. EDPs inhibit angiogenesis. (A) The 19,20-EDP inhibited VEGF-induced angiogenesis in a Matrigel plug assay in C57BL/6 mice in a dose-dependent manner (n = 4–6 mice per group). Dose of VEGF is 100 ng per gel. (Left)Quantification of angiogenesis using hemoglobin assay. (Right) Image of representative gels and immunohistochemistry for CD31. (B) All EDP regioisomers inhibited VEGF-induced angiogenesis in mice (n = 6–10 mice per group). Dose of EDP regioisomer was 10 μgpergel.(C) The 19,20-EDP inhibited endothelial tube formation after 6-h treatment in HUVECs. (Left) Calcein AM-stained HUVEC microscopy. (Right) Quantification of tube formation. (D) The 19,20-EDP inhibited VEGF-induced cell migration of HUVECs on extracellular matrix protein fibronectin after 18-h treatment in HUVECs. (Left) Crystal violet-stained HUVEC microscopy. (Right)Quantification of migrated cells. (E) The 19,20-EDP inhibited MMP activity after 4-h treatment in HUVECs. (F)Atadoseof1μM, 19,20-EDP not 14,15-EET, inhibited VEGF-induced VEGFR2 phosphorylation after 10-min treatment in HUVECs.